English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry

MPS-Authors
/persons/resource/persons172989

Stieg,  Mareike R.
RG Clinical Neuroendocrinology, Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80305

Dimopoulou,  Christina
RG Clinical Neuroendocrinology, Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80539

Stalla,  Günter K.
RG Clinical Neuroendocrinology, Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Berr, C. M., Stieg, M. R., Deutschbein, T., Quinkler, M., Schmidmaier, R., Osswald, A., et al. (2017). Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 176(6), 737-746. doi:10.1530/EJE-16-0689.


Cite as: https://hdl.handle.net/21.11116/0000-0001-7B73-4
Abstract
Background: Cushing's syndrome (CS) is characterized by an excessive secretion of glucocorticoids that results in a characteristic clinical phenotype. One feature of clinical hypercortisolism is breakdown of protein metabolism translating into clinical consequences including glucocorticoid-induced myopathy. While surgery is effective in control of cortisol excess, the effect of biochemical remission on muscular function is yet unclear. Methods: In a cross-sectional study we analyzed 47 patients with CS during the florid phase (ActiveCS). 149 additional patients were studied 2-53 years (mean: 13 years) after surgery in biochemical long-term remission (RemissionCS). Also, 93 rule-out CS patients were used as controls (CON). All subjects were assessed for grip strength using a hand grip dynamometer and underwent the chair rising test (CRT). Results: Hand grip strength (85% vs 97% of norm, P = 0.002) and the CRT performance (9.5 s vs 7.1 s, P = 0.001) were significantly lower in ActiveCS compared to the CON group. Six months after treatment grip strength further decreased in CS (P = 0.002) and CRT performance remained impaired. The RemissionCS group (mean follow-up 13 years) had reduced hand grip strength (92% compared to normal reference values for dominant hand, P < 0.001). The chair rising test performance was at 9.0 s and not significantly different from the ActiveCS group (P = 0.45). Conclusion: CS affects muscle strength in the acute phase, but functional impairment remains detectable also during long-term follow-up despite biochemical remission.